bioAffinity Technologies (BIAF) Receivables - Net (2021 - 2026)

bioAffinity Technologies has disclosed Receivables - Net across 6 years of filings, most recently posting $685235.0 for Q1 2026.

• In Q1 2026, Receivables - Net fell 28.9% year-over-year to $685235.0; the TTM figure through Mar 2026 stood at $685235.0 (down 28.9% YoY), while the FY2025 annual figure was $541962.0, down 52.43% from the prior year.
• Receivables - Net grew to $685235.0 in Q1 2026, from $541962.0 in the prior quarter.
• Over the last five years, Receivables - Net for BIAF reached as high as $1.6 million in Q2 2024 and fell as low as $9930.0 in Q3 2022.
• The 5-year median for Receivables - Net is $685235.0 (2026), against an average of $685944.9.
• Annual changes were most pronounced in 2023 — Receivables - Net jumped 11062.28% — and 2025, when it slumped 73.56%.
• A 5-year view of Receivables - Net shows it stood at $10489.0 in 2022, then soared by 7638.34% to $811674.0 in 2023, then surged by 40.35% to $1.1 million in 2024, then slumped by 52.43% to $541962.0 in 2025, then gained by 26.44% to $685235.0 in 2026.
• According to Business Quant data, Receivables - Net over the past three periods registered $685235.0, $541962.0, and $448990.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.